GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Minerva Surgical Inc (OTCPK:UTRS) » Definitions » Debt-to-EBITDA

Minerva Surgical (Minerva Surgical) Debt-to-EBITDA : -2.39 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Minerva Surgical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Minerva Surgical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $12.27 Mil. Minerva Surgical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $31.28 Mil. Minerva Surgical's annualized EBITDA for the quarter that ended in Sep. 2023 was $-18.24 Mil. Minerva Surgical's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -2.39.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Minerva Surgical's Debt-to-EBITDA or its related term are showing as below:

UTRS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.31   Med: 21   Max: 118.5
Current: -2.15

During the past 4 years, the highest Debt-to-EBITDA Ratio of Minerva Surgical was 118.50. The lowest was -2.31. And the median was 21.00.

UTRS's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs UTRS: -2.15

Minerva Surgical Debt-to-EBITDA Historical Data

The historical data trend for Minerva Surgical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Surgical Debt-to-EBITDA Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
-2.31 118.50 43.98 -1.98

Minerva Surgical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 -4.04 -1.27 -1.97 -2.39

Competitive Comparison of Minerva Surgical's Debt-to-EBITDA

For the Medical Devices subindustry, Minerva Surgical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Surgical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minerva Surgical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Minerva Surgical's Debt-to-EBITDA falls into.



Minerva Surgical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Minerva Surgical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.249 + 37.441) / -20.073
=-1.98

Minerva Surgical's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.272 + 31.279) / -18.24
=-2.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Minerva Surgical  (OTCPK:UTRS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Minerva Surgical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Minerva Surgical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Surgical (Minerva Surgical) Business Description

Traded in Other Exchanges
N/A
Address
4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.
Executives
Daniel Cohen director C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Uri Geiger director, 10 percent owner 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Todd Usen director, officer: Chief Executive Officer C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054
Derrick Sung director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
David M Clapper director, officer: President and CEO 3003 TASMAN DRIVE, SANTA CLARA CA 95054
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jaffe Ross A Md director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Evgueni V. Skalnyi officer: VP Medical Affairs C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Dominique J. Filloux officer: COO C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Joel R Jung officer: CFO 1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Niquette L. Hunt director SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081
Jill Anderson director 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202